HDR-mediated gene replacement has been used to correct disease-causing point mutations in the β-globin (HBB) gene in HSCs and patient-derived HSPCs to treat β-thalassemia and sickle cell disease (SCD) (63). Here, HBB is linked to sickle cell disease.